Regulatory Filings • Apr 12, 2016
Regulatory Filings
Open in ViewerOpens in native device viewer
Press Release
Romainville (France), Boston (Massachusetts), April 12, 2016 – BIOPHYTIS (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced today that posters related to the Company's two lead compounds, BIO 101 for Sarcopenic Obestity and BIO 201 for Dry AMD, will be presented at the International Conference on Frailty and Sarcopenia Research (ICFSR) 2016 in April, and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May, respectively.
Details of the presentations are below.
| Poster #: | 53 |
|---|---|
| Title: | A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of |
| BIO101 on Sarcopenic Obesity | |
| Date: | Thursday, April 28, 2016 |
| Location: | Pennsylvania Convention Center |
| Presenter: | Waly Dioh, Ph.D., Director of Clinical Development, Biophytis |
| B0291 |
|---|
| 1119 - B0291 |
| BIO201: A New Drug Candidate for the Treatment of Dry AMD |
| New Drugs |
| Sunday, May 1, 2016 |
| 3:15 – 5:00 PM |
| Washington State Convention Center |
| Valérie Fontaine, Ph.D., Senior Scientist, Institut de la Vision |
BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS. has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry agerelated macular degeneration (AMD).
The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.
BIOPHYTIS is eligible for the French PEA-PME regime.
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forwardlooking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
BIOPHYTIS Stanislas VEILLET CEO [email protected] Tel : +33 1 41 83 66 00
Milestones Bruno ARABIAN [email protected] Tel : +33 1 83 62 34 84 Mob : +33 6 87 88 47 26 LifeSci Advisors Chris MAGGOS Managing Director, Europe [email protected] Tel : +41 79 367 6254
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.